|Table of Contents|

The clinical value of testing cfDNA fragments length based on Alu-qPCR technique in the differentiation of benign and malignant pulmonary nodules

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 06
Page:
944-949
Research Field:
Publishing date:

Info

Title:
The clinical value of testing cfDNA fragments length based on Alu-qPCR technique in the differentiation of benign and malignant pulmonary nodules
Author(s):
WANG Yuxuan; SU Chongyu; LIU Zhidong
Beijing Tuberculosis and Thoracic Tumor Research Institute,Beijing Chest Hospital,Beijing 101149,China.
Keywords:
pulmonary node; lung cancer; cfDNA; tumor biomarker; liquid biopsy
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.06.008
Abstract:
Objective:To evaluate the value of cfDNA segment concentration testing and apoptosis index calculation in differentiating benign and malignant pulmonary nodules.Methods:We collected and purified the plasma of patients with pulmonary nodules,evaluated the cfDNA concentration,apoptosis index,and traditional tumor protein markers.Their relationship with clinicopathological parameters was analyzed.Results:The short fragments content of malignant pulmonary node and benign pulmonary node patients was 129.86,91.12 ng/mL (P＞0.05).Long fragments content was 33.95,38.24 ng/mL (P＜0.05),and apoptosis index was 9.44,5.35(P＜0.05).Long fragment cfDNA concentration,apoptosis index can be used as potential detection indexes.Critical value was 6.22,29.50 ng/mL.Corresponding sensitivity was 0.63,0.74,corresponding.Specificity was 0.77,0.85.The level of tumor markers in patients with benign and malignant nodules was not statistically significant.Conclusion:cfDNA detection has potential application value in judging the nature of pulmonary nodules,which can indicate the pathological properties of pulmonary nodules.Tumor markers have a suggestive effect on the invasion and metastasis of known pathological types of pulmonary nodules,which can be used for metastasis and recurrence monitoring.Combine those two indexes can provide a reference for the clinical intervention of pulmonary nodules in different periods.

References:

［1］CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［2］HOREWEG N,SCHOLTEN ET,DE JONG PA,et al.Detection of lung cancer through low-dose CT screening (NELSON):a prespecified analysis of screening test performance and interval cancers［J］.Lancet Oncol,2014,15(12):1342-1350.
［3］BLACKHALL F,FRESE KK,SIMPSON K,et al.Will liquid biopsies improve outcomes for patients with small-cell lung cancer［J］.Lancet Oncol,2018,19(9):e470-e481.
［4］CHAUDHURI AA,CHABON JJ,LOVEJOY AF,et al.Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling［J］.Cancer Discov,2017,7(12):1394-1403.
［5］SNYDER MW,KIRCHER M,HILL AJ,et al.Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin［J］.Cell,2016,164(1):57-68.
［6］UNDERHILL HR,KITZMAN JO,HELLWIG S,et al.Fragment length of circulating tumor DNA［J］.PLoS Genet,2016,12(7):e1006162.
［7］HUSSEIN NA,MOHAMED SN,AHMED MA.Plasma ALU-247,ALU-115,and cfDNA integrity as diagnostic and prognostic biomarkers for breast cancer［J］.Appl Biochem Biotechnol,2019,187(3):1028-1045.
［8］PRICE AL,ESKIN E,PEVZNER PA.Whole-genome analysis of Alu repeat elements reveals complex evolutionary history［J］.Genome Res,2004,14(11):2245-2252.
［9］CHEN H,SUN LY,ZHENG HQ,et al.Total serum DNA and DNA integrity:diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma［J］.Pathology,2012,44(4):318-324.
［10］MOULIERE F,CHANDRANANDA D,PISKORZ AM,et al.Enhanced detection of circulating tumor DNA by fragment size analysis［J］.Sci Transl Med,2018,10(466):eaat4921.
［11］UMETANI N,KIM J,HIRAMATSU S,et al.Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer:direct quantitative PCR for ALU repeats［J］.Clin Chem,2006,52(6):1062-1069.
［12］MANDEL P,METAIS P.Les acides nucléiques du plasma sanguin chez l' homme［J］.C R Seances Soc Biol Fil,1948,142(3-4):241-243.
［13］LEON SA,SHAPIRO B,SKLAROFF DM,et al.Free DNA in the serum of cancer patients and the effect of therapy［J］.Cancer Res,1977,37(3):646-650.
［14］CRISTIANO S,LEAL A,PHALLEN J,et al.Genome-wide cell-free DNA fragmentation in patients with cancer［J］.Nature,2019,570(7761):385-389.
［15］SIRAVEGNA G,MUSSOLIN B,VENESIO T,et al.How liquid biopsies can change clinical practice in oncology［J］.Ann Oncol,2019,30(10):1580-1590.
［16］JAHR S,HENTZE H,ENGLISCH S,et al.DNA fragments in the blood plasma of cancer patients:quantitations and evidence for their origin from apoptotic and necrotic cells［J］.Cancer Res,2001,61(4):1659-1665.
［17］LENG S,ZHENG J,JIN Y,et al.Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis［J］.Clinica Chimica Acta,2018,477:160-165.

Memo

Memo:
北京市通州区科技计划（编号：KJ2019CX007）
Last Update: 1900-01-01